A single-masked study involving 120 HF patients reported significant improvements in NYHA class, BNP, LVEF, and metabolic biomarkers after SMI administration, with superior effects compared to trimetazidine, suggesting a synergistic advantage of multitarget interventions (Wang et al., 2020b). The gene discussed is NPPB; the disease is hydrops fetalis.